[{"id":"7158f3c8-048e-44f4-84c4-9fea0fbb9783","acronym":"","url":"https://clinicaltrials.gov/study/NCT06282978","created_at":"2024-02-29T03:33:45.743Z","updated_at":"2024-07-02T16:35:16.129Z","phase":"Phase 2","brief_title":"Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes","source_id_and_acronym":"NCT06282978","lead_sponsor":"PETHEMA Foundation","biomarkers":" KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81","pipe":" | ","alterations":" CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression","tags":["KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elrexfio (elranatamab-bcmm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/23/2023","start_date":" 11/23/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-03-06"},{"id":"13e31fc7-6242-40ee-99d8-2f2a2731674e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05512104","created_at":"2022-08-23T14:55:30.941Z","updated_at":"2024-07-02T16:36:05.049Z","phase":"","brief_title":"Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression","source_id_and_acronym":"NCT05512104","lead_sponsor":"Assiut University","biomarkers":" NCAM1 • CD200","pipe":" | ","alterations":" NCAM1 expression","tags":["NCAM1 • CD200"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2022-08-23"},{"id":"21306679-e323-4aa8-8301-c11a68536607","acronym":"","url":"https://clinicaltrials.gov/study/NCT04546945","created_at":"2021-01-18T21:45:01.898Z","updated_at":"2024-07-02T16:36:06.914Z","phase":"","brief_title":"Aberrant Expression of CD56 in Patients With Hematologic Malignancies.","source_id_and_acronym":"NCT04546945","lead_sponsor":"Asmaa Hassan mohamed Abdel Mawjoud","biomarkers":" NCAM1","pipe":" | ","alterations":" NCAM1 expression","tags":["NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-07-22"},{"id":"ea505106-f0f3-438c-81cb-5a4b65a69585","acronym":"","url":"https://clinicaltrials.gov/study/NCT02452554","created_at":"2021-01-18T11:45:46.897Z","updated_at":"2024-07-02T16:36:18.487Z","phase":"Phase 2","brief_title":"Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma","source_id_and_acronym":"NCT02452554","lead_sponsor":"Children's Oncology Group","biomarkers":" NCAM1","pipe":" | ","alterations":" NCAM1 expression","tags":["NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lorvotuzumab mertansine (IMGN901)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/12/2015","start_date":" 10/12/2015","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2022-01-13"},{"id":"7f2b2a36-c6b8-470e-9ddb-f0be399d1289","acronym":"REGULATe","url":"https://clinicaltrials.gov/study/NCT00626483","created_at":"2021-01-18T02:19:44.667Z","updated_at":"2024-07-02T16:36:33.628Z","phase":"Phase 1","brief_title":"Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia","source_id_and_acronym":"NCT00626483 - REGULATe","lead_sponsor":"Gary Archer Ph.D.","biomarkers":" IL2RA • CD4 • IL7R • NCAM1 • ISG20","pipe":" | ","alterations":" NCAM1 expression","tags":["IL2RA • CD4 • IL7R • NCAM1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • umitrelimorgene autodencel (ITI-1000)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 04/24/2007","start_date":" 04/24/2007","primary_txt":" Primary completion: 07/06/2016","primary_completion_date":" 07/06/2016","study_txt":" Completion: 07/06/2016","study_completion_date":" 07/06/2016","last_update_posted":"2021-03-09"},{"id":"792a891b-6076-4a79-9e41-755c5c16dc11","acronym":"","url":"https://clinicaltrials.gov/study/NCT02420873","created_at":"2021-01-18T11:34:35.992Z","updated_at":"2024-07-02T16:37:07.404Z","phase":"Phase 2","brief_title":"An Open-label Phase II Study of Lorvotuzumab Mertansine","source_id_and_acronym":"NCT02420873","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • NCAM1","pipe":" | ","alterations":" NCAM1 expression","tags":["FLT3 • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lorvotuzumab mertansine (IMGN901)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 05/12/2015","start_date":" 05/12/2015","primary_txt":" Primary completion: 06/06/2017","primary_completion_date":" 06/06/2017","study_txt":" Completion: 06/06/2017","study_completion_date":" 06/06/2017","last_update_posted":"2018-08-28"}]